close 76% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 76% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Home・Aandelen Lijst・Lyell Immunopharma Inc
Search

Lyell Immunopharma Inc

Gesloten

8.99 -3.64

Sell

Prijsupdate 26 jun 2025, 19:58 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.76

Max

9.3

Belangrijke statistieken

By Trading Economics

Inkomsten

140M

-52M

Verkoop

-4K

7K

EPS

-3.6

Winstmarge

-745,642.857

Werknemers

300

EBITDA

3.7M

-54M

Aanbevelingen

By TipRanks

Aanbevelingen

Sell

12 Maanden Prognose

+18.41% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

133M

Vorige openingsprijs

12.63

Vorige sluitingsprijs

8.99

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

0.4217 / 0.4691 Steun & Weerstand

Lyell Immunopharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jun 2025, 23:49 UTC

Winsten

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

DJ

Lezen

26 jun 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

DJ

Lezen

26 jun 2025, 21:30 UTC

Winsten

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

DJ

Lezen

26 jun 2025, 21:07 UTC

Winsten

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

DJ

Lezen

26 jun 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

DJ

Lezen

26 jun 2025, 23:39 UTC

Marktinformatie

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

DJ

Lezen

26 jun 2025, 23:34 UTC

Acquisities, Fusies, Overnames

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

DJ

Lezen

26 jun 2025, 23:33 UTC

Acquisities, Fusies, Overnames

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

DJ

Lezen

26 jun 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Wesfarmers Will No Longer Receive Earnings From BWP Management

DJ

Lezen

26 jun 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

DJ

Lezen

26 jun 2025, 23:31 UTC

Acquisities, Fusies, Overnames

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

DJ

Lezen

26 jun 2025, 23:31 UTC

Acquisities, Fusies, Overnames

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

DJ

Lezen

26 jun 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

DJ

Lezen

26 jun 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

DJ

Lezen

26 jun 2025, 23:19 UTC

Acquisities, Fusies, Overnames

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

DJ

Lezen

26 jun 2025, 22:06 UTC

Winsten

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Lezen

26 jun 2025, 21:15 UTC

Winsten

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

DJ

Lezen

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

DJ

Lezen

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

DJ

Lezen

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

DJ

Lezen

26 jun 2025, 21:07 UTC

Winsten

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Lezen

26 jun 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

DJ

Lezen

26 jun 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

DJ

Lezen

26 jun 2025, 21:06 UTC

Marktinformatie

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

DJ

Lezen

26 jun 2025, 21:05 UTC

Acquisities, Fusies, Overnames

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Lezen

26 jun 2025, 21:05 UTC

Acquisities, Fusies, Overnames

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Lezen

26 jun 2025, 20:52 UTC

Winsten

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

DJ

Lezen

26 jun 2025, 20:51 UTC

Winsten

Correct: Nike 4Q Net $211M, Not $200M >NKE

DJ

Lezen

26 jun 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

26 jun 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Lyell Immunopharma Inc Prognose

Koersdoel

By TipRanks

18.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11 USD  18.41%

Hoogste 12 USD

Laagste 10 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lyell Immunopharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

3 ratings

0

Buy

2

Hold

1

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Lyell Immunopharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.4217 / 0.4691Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Weak Bearish Evidence

There is one bearish event.

Lange Termijn

No Evidence

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

795.48

↑ +0.43%

JNJ

Johnson and Johnson

152.14

↓-0.14%

ABBV

AbbVie Inc

186.94

↑ +0.72%

NVO

Novo Nordisk A-S

67.74

↑ +0.61%

UNH

UnitedHealth Group Inc

302.46

↑ +0.12%